Repopulation Efficiencies of Adult Hepatocytes, Fetal Liver Progenitor Cells, and Embryonic Stem Cell-Derived Hepatic Cells in Albumin-Promoter-Enhancer Urokinase-Type Plasminogen Activator Mice

• DOI: 10.2353/ajpath.2009.090117
• Publication Date: 2009-08-29T01:33:14Z
• Authors: Dhivya Haridass; Qinggong Yuan; Pablo D. Becker; Tobias Cantz; Marcus Iken; Michael Rothe; Nidhi Narain; Michael Bock; Miriam Nörder; Nicolas Legrand; Heiner Wedemeyer; Kees Weijer; Hergen Spits; Michael P. Manns; Jun Cai; Hongkui Deng; James P. Di Santo; Carlos A. Guzman; Michael Ott
• Keywords: Adult; 0303 health sciences; Urokinase-Type Plasminogen Activator; Mice, Inbred C57BL; Mice; 03 medical and health sciences; Enhancer Elements, Genetic; Fetus; Liver; Cell Movement; Albumins; Hepatocytes; Animals; Humans; alpha-Fetoproteins; Embryonic Stem Cells; Cell Proliferation; Stem Cell Transplantation

Fetal liver progenitor cell suspensions (FLPC) and hepatic precursor cells derived from embryonic stem cells (ES-HPC) represent a potential source for liver cell therapy. However, the relative capacity of these cell types to engraft and repopulate a recipient liver compared with adult hepatocytes (HC) has not been comprehensively assessed. We transplanted mouse and human HC, FLPC, and ES-HPC into a new immunodeficient mouse strain (Alb-uPA(tg(+/-))Rag2(-/-)gamma(c)(-/-) mice) and estimated the percentages of HC after 3 months. Adult mouse HC repopulated approximately half of the liver mass (46.6 +/- 8.0%, 1 x 10(6) transplanted cells), whereas mouse FLPC derived from day 13.5 and 11.5 post conception embryos generated only 12.1 +/- 3.0% and 5.1 +/- 1.1%, respectively, of the recipient liver and smaller cell clusters. Adult human HC and FLPC generated overall less liver tissue than mouse cells and repopulated 10.0 +/- 3.9% and 2.7 +/- 1.1% of the recipient livers, respectively. Mouse and human ES-HPC did not generate HC clusters in our animal model. We conclude that, in contrast to expectations, adult HC of human and mouse origin generate liver tissue more efficiently than cells derived from fetal tissue or embryonic stem cells in a highly immunodeficient Alb-uPA transgenic mouse model system. These results have important implications in the context of selecting the optimal strategy for human liver cell therapies.